- Home
- LIF vs AKRO Comparison
LIF vs AKRO Comparison
Compare LIF & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIF
- AKRO
- Stock Information
- Founded
- LIF 2008
- AKRO 2017
- Country
- LIF United States
- AKRO United States
- Employees
- LIF N/A
- AKRO N/A
- Industry
- LIF
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- LIF
- AKRO Health Care
- Exchange
- LIF Nasdaq
- AKRO Nasdaq
- Market Cap
- LIF 4.8B
- AKRO 3.9B
- IPO Year
- LIF N/A
- AKRO 2019
- Fundamental
- Price
- LIF $61.97
- AKRO $54.20
- Analyst Decision
- LIF Strong Buy
- AKRO Strong Buy
- Analyst Count
- LIF 7
- AKRO 6
- Target Price
- LIF $55.57
- AKRO $82.50
- AVG Volume (30 Days)
- LIF 1.1M
- AKRO 1.8M
- Earning Date
- LIF 08-11-2025
- AKRO 08-08-2025
- Dividend Yield
- LIF N/A
- AKRO N/A
- EPS Growth
- LIF N/A
- AKRO N/A
- EPS
- LIF 0.04
- AKRO N/A
- Revenue
- LIF $396,881,000.00
- AKRO N/A
- Revenue This Year
- LIF $27.69
- AKRO N/A
- Revenue Next Year
- LIF $22.16
- AKRO N/A
- P/E Ratio
- LIF $1,481.14
- AKRO N/A
- Revenue Growth
- LIF 26.15
- AKRO N/A
- 52 Week Low
- LIF $28.94
- AKRO $21.02
- 52 Week High
- LIF $65.79
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- LIF N/A
- AKRO 62.96
- Support Level
- LIF N/A
- AKRO $53.61
- Resistance Level
- LIF N/A
- AKRO $56.49
- Average True Range (ATR)
- LIF 0.00
- AKRO 2.40
- MACD
- LIF 0.00
- AKRO -0.08
- Stochastic Oscillator
- LIF 0.00
- AKRO 65.93
About LIF Life360 Inc. Common Stock
Life360 is the world's largest family-focused social network, with over 50 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.